Lithuanian University of Health Sciences Research Management System (CRIS)





 

Publication:
Gene therapy for spinal muscular atrophy: First experience in Lithuania

cris.virtual.departmentLietuvos sveikatos mokslų universitetas (302536989)
cris.virtualsource.author-orcid4002dd9a-a870-479e-9f78-3c889a75216c
cris.virtualsource.department4002dd9a-a870-479e-9f78-3c889a75216c
datacite.subject.fosMedical and Health sciences::Clinical medicine::Clinical neurology
dc.contributor.authorDambrauskienė, Milda
dc.coverage.spatialLV
dc.date.accessioned2024-06-11T08:27:56Z
dc.date.accessioned2024-06-12T11:40:12Z
dc.date.available2024-06-11T08:27:56Z
dc.date.issued2024-05-23
dc.description.abstractObjectives To present the first case of spinal muscular atrophy (SMA) treated with gene therapy in Lithuania. Materials and Methods Here we report a patient with SMA type 1 who received onasemnogene abeparvovec in Lithuania. Results Our patient is a 2,8 year old girl, who was diagnosed with SMA type 1 at the age of 15 weeks. She received the first injection of nusinersen at the age of 18 weeks. Her motor functions were assessed using CHOP INTEND scale and the scores improved from 14/64 before treatment up to 35/64 and 46/64 points after four and five doses of nusinersen, respectively. Nevertheless, her bulbar function was declining. At 7 months, due to respiratory insufficiency and frequent respiratory infections NIV was established. She also had feeding difficulties and failure to thrive, and a G-tube was inserted at the age of 13 months. At the same time the family initiated their own fundraising campaign, attracting a lot of attention from the media and politicians. Finally, with the partial reimbursement from the government of Lithuania, the girl was able to get dosed with onasemnogene abeparvovec at the age of 20 months (body weight was 9,2 kg). After the infusion, blood tests were performed regularly, and the only side effect we observed was elevation of transaminases. According to the protocol, the patient was put on steroids for three months. After one year after gene therapy, the patient can sit independently, she can stand with support. No major changes in bulbar function were noticed so far. Her CHOP INTEND score increased by two points (47/64 points). Conclusions To our knowledge, this is the first case of gene therapy for SMA in the Baltic countries. We consider it to be successful, as the patient was almost two years old, pretreated with nusinersen, and the risk of complications was higher than in young patients.en
dc.description.sponsorshipLSMU ligoninė Kauno klinikos (135163499)*
dc.description.sponsorshipLietuvos sveikatos mokslų universitetas (302536989)*
dc.description.sponsorshipNeurologijos klinika (K150000)*
dc.description.versionOriginalus / Original
dc.identifier.urihttps://hdl.handle.net/20.500.12512/245026
dc.language.isoen
dc.publisherJūrmala : Baltic Child Neurology Association
dc.relation.publication17th Conference of Baltic Child Neurology Association : May 23-25, 2024, Jūrmala, Latvia : Abstracts
dc.rightsintranet access*
dc.subject.classificationKonferencijų tezės nerecenzuojamame leidinyje / Conference theses in non-peer-reviewed publication (T2)
dc.subject.otherMedicina / Medicine (M001)
dc.titleGene therapy for spinal muscular atrophy: First experience in Lithuaniaen
dc.typetext::conference output::conference proceedings::conference paper
dcterms.dateSubmitted2024
dspace.entity.typePublication
localcerif.author.code302536989-K150000
localcerif.pages1*
oaire.citation.endPage22
oaire.citation.startPage22
oairecerif.author.affiliationNeurologijos klinika (K150000)

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Abstracts_BCNA2024.pdf
Size:
2.05 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.1 KB
Format:
Item-specific license agreed to upon submission
Description: